George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 267.50
Bid: 265.00
Ask: 268.50
Change: 0.00 (0.00%)
Spread: 3.50 (1.321%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 267.50
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to host R&D Briefings

21 Mar 2017 10:08

RNS Number : 0625A
Hutchison China Meditech Limited
21 March 2017
 

Press ReleaseChi-Med to host R&D Briefings on March 29 & 30, 2017

London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an overview of the Company's clinical pipeline of eight novel drug candidates. The events for analysts and investors will take place in London on Wednesday, March 29, and in New York on Thursday, March 30, 2017.

 

Chi-Med is a China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market. The Company has 30 ongoing clinical trials with eight novel drug candidates, which are expected to report a steady flow of pivotal Phase III trial results from this year onwards. Chi-Med's first drug is targeted to launch next year in China.

 

The Chi-Med management team will outline the Company's R&D strategy and discuss its drug candidate pipeline during the briefings.

 

Date:

Wednesday, March 29, 2017

Thursday, March 30, 2017

City:

London

New York

Time:

9:15am Registration

9:30am-12:30pm Program Presentation

Lunch will be provided afterwards

8:00am Registration & Breakfast

8:30am-11:30am Program Presentation

Address:

South Place Hotel, 3 South Place, London, EC2M 2AF

W Hotel, 541 Lexington Ave, New York, NY 10022

Keynote Speaker:

Dr Susan Galbraith, Vice President, AstraZeneca PLC ("AstraZeneca")

 

The briefing on Wednesday, March 29, 2017 in London will begin with a keynote presentation from Dr Susan Galbraith, Vice President of Oncology Innovative Medicines and Early Development at AstraZeneca.

 

Mr Christian Hogg, Chief Executive Officer; Dr Weiguo Su, Executive Vice President and Chief Scientific Officer; Dr Zhenping Wu, Senior Vice President of Pharmaceutical Sciences; and Dr May Wang, Senior Vice President of Business Development & Strategic Alliances, will be presenting on Chi-Med's research & development and partnering activities. Chi-Med currently has partnerships with AstraZeneca, Eli Lilly and Company and Nestlé Health Science S.A.

 

To register for the London briefing, please contact Dr Marine Perrier by telephone at +44 20 7282 1068 or by email at marine.perrier@citigatedr.co.uk.

 

To register for the New York briefing, please contact Matt Beck by telephone at +1 646 378 2933 or by email at mbeck@troutgroup.com.

 

No new material trading or financial information will be disseminated at the meeting. Following the meeting, the presentations will be made available at http://www.chi-med.com/news/.

 

 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

 

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med's current expectations regarding future events, including its expectations for the clinical development of savolitinib, fruquintinib, sulfatinib, epitinib, theliatinib, HMPL-523, HMPL-689, HMPL-453 and other drug research and development projects, including plans for clinical studies, its expectations as to whether such studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates, timing and availability of subjects meeting a study's inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of drug candidate sulfatinib to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions, to gain commercial acceptance after obtaining regulatory approval, the potential market of sulfatinib for a targeted indication and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

Investor Enquiries

Christian Hogg, CEO

+852 2121 8200

UK and International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk

US Based Media Enquiries

Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

bmiles@bmccommunications.com

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

sduffy@bmccommunications.com

Investor Relations

Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

mbeck@troutgroup.com

David Dible, Citigate Dewe Rogerson

+44 7967 566 919 (Mobile)

david.dible@citigatedr.co.uk

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts

+44 (20) 7886 2500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEANDFASXXEEF
Date   Source Headline
28th Mar 20247:00 amRNSSavolitinib sNDA Accepted in China
22nd Mar 20247:00 amRNSInitiation of Registration Stage of P2/3 Trial
14th Mar 20249:00 amRNSLTIP and Share Option Scheme
5th Mar 20248:30 amRNSVesting of awards under the LTIP
28th Feb 202412:45 pmRNSPublication of Form 20-F
28th Feb 202411:30 amRNS2023 Full Year Results and Business Updates
7th Feb 20247:00 amRNSPresentation of Phase III Data on Fruquintinib
2nd Feb 20248:37 amRNSInmagene Exercises Option for Two Drug Candidates
1st Feb 20248:30 amRNSHUTCHMED to Announce 2023 Final Results
30th Jan 20247:12 amRNSHUTCHMED Receives Marketing Approval in Hong Kong
11th Jan 20247:00 amRNSSovleplenib NDA Granted Priority Review in China
29th Dec 20238:30 amRNSTotal Voting Rights
29th Dec 20238:30 amRNSBlocklisting Six Monthly Return
21st Dec 202310:00 amRNSOverseas Regulatory Announcement
13th Dec 20237:00 amRNSInclusion in National Reimbursement Drug List
13th Dec 20237:00 amRNSCompleted Enrollment of Phase II/III Trial
7th Dec 202310:04 amRNSOverseas Regulatory Announcement
1st Dec 20237:00 amRNSClinical Data to be Presented at Congresses
30th Nov 20238:30 amRNSTotal Voting Rights
9th Nov 20237:00 amRNSU.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib)
24th Oct 20239:30 amRNSVesting of awards under the LTIP
16th Oct 20239:30 amRNSClinical Data to be Presented at ESMO 2023
29th Sep 20239:30 amRNSNDA Submission for Fruquintinib in Japan
29th Sep 20239:30 amRNSTotal Voting Rights
14th Sep 20239:30 amRNSDirector’s Share Dealing
12th Sep 20239:30 amRNSPhase IIIb Savolitinib Results at WCLC 2023
12th Sep 20237:00 amRNSPatient Enrollment Completed for Bridging Study
31st Aug 20239:30 amRNSTotal Voting Rights
29th Aug 20237:00 amRNSBTD in China for Savolitinib for Gastric Cancer
21st Aug 20237:00 amRNSSovleplenib Phase 3 Study Meets Primary Endpoint
7th Aug 20239:30 amRNSExercise of Share Options by a Director
31st Jul 202312:00 pmRNSInterim Results and Business Updates
20th Jul 20237:00 amRNSBreakthrough Therapy Designation for Fruquintinib
13th Jul 20239:30 amRNSChanges to Board and Technical Committee
10th Jul 20237:00 amRNSPhase 1 Study of HMPL-415 Initiated
29th Jun 20239:30 amRNSBlocklisting Six Monthly Return
26th Jun 20239:30 amRNSHUTCHMED to Announce 2023 Half-Year Results
16th Jun 20237:00 amRNSPhase III FRESCO-2 Results in The Lancet
15th Jun 20233:39 pmRNSMAA of Fruquintinib Validated by the EMA
9th Jun 202310:30 amRNSHUTCHMED Highlights Presentations at EHA and ICML
6th Jun 202310:00 amRNSLTIP and Share Option Scheme
31st May 20239:30 amRNSTotal Voting Rights
26th May 20237:00 amRNSFruquintinib NDA Granted Priority Review by FDA
26th May 20237:00 amRNSHUTCHMED Highlights Presentations at ASCO 2023
17th May 20239:30 amRNSStandard form for notification of major holdings
12th May 20231:15 pmRNSAnnual General Meeting Poll Results
12th May 20239:30 amRNSBoard of Directors and Board Committee Membership
10th May 20239:30 amRNSAppointment of Independent NED
28th Apr 20239:30 amRNSTotal Voting Rights
21st Apr 20239:30 amRNSVesting of awards under the LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.